The standard way to assess a patient's response to chemotherapy is to use computed tomography (CT) to measure tumor size using uni-dimensional (RECIST) or bi-dimensional (WHO) criteria. The same standards are used to gauge the effectiveness of investigational therapies in patients with lung cancer. This methodology has changed little in the past 30 years despite the emergence of new therapies and advances in imaging technology. We and others have found that only determining the changes in the size of tumors in one or two dimensions does not adequately capture the effects of novel therapies on primary tumors and metastases. Radiographic changes in tumors treated with epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib or erlotinib or inhibitors of angiogenesis such as bevacizumab do not necessarily occur at the same magnitude or speed as observed in those individuals treated with standard cytotoxic therapies. With these newer agents, tumors respond by undergoing cystic change, central necrosis and density changes that may not be captured by conventional measurements of the largest lesion diameter. Functional changes that can only be captured on PET FDG or FIT imaging also occur. The goals of this study are to investigate the use of imaging to assess early response and progression in groups of patients receiving different types of systemic therapy (standard cytotoxic, EGFR-TKI and antiangiogenic standard) for lung cancer by correlating tumor response using advanced imaging techniques with biomarkers as well as with disease-free progression and survival. Specifically, 1.To evaluate categorical response assessment using RECIST, bi-dimensional, volumetric measures on CT and changes in metabolism on FDG-PET and proliferation on FLT-PET in patients on cytotoxic, EGFR-TKI and antiangiogenic therapy and to correlate the Best Overall Response and Progression Free Survival derived from these measurements of response with overall survival. 2. To compare total plasma DNA results with image based response (best overall response and progression free survival) and overall survival. 3. To determine if the use of a continuous scale best overall response better predicts than the categorical response assessment currently used. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA125143-01A1
Application #
7321437
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Farahani, Keyvan
Project Start
2007-08-07
Project End
2012-06-30
Budget Start
2007-08-07
Budget End
2008-06-30
Support Year
1
Fiscal Year
2007
Total Cost
$354,322
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Zhao, Binsheng; Tan, Yongqiang; Bell, Daniel J et al. (2013) Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol 82:959-68
Tan, Yongqiang; Guo, Pingzhen; Mann, Helen et al. (2012) Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours. Cancer Imaging 12:497-505
Oxnard, Geoffrey R; Zhao, Binsheng; Sima, Camelia S et al. (2011) Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 29:3114-9
Zhao, Binsheng; Oxnard, Geoffrey R; Moskowitz, Chaya S et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-53
Moskowitz, Chaya S; Jia, Xiaoyu; Schwartz, Lawrence H et al. (2009) A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 45:300-10
Zhao, Binsheng; James, Leonard P; Moskowitz, Chaya S et al. (2009) Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252:263-72